Compare JD.Com Inc (JD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs TG Therapeutics Inc — how do they compare? JD.Com Inc trades at $30.59 (market cap $41.80B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: JD.Com Inc is far larger — about 5.1× TG Therapeutics Inc's market cap, and JD.Com Inc pays a 3.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JD | TGTX | |
|---|---|---|
Market Cap | $41.80B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $59.06 |
52-Week Low | $25.19 | $26.39 |
Enterprise Value | $27.96B | $8.50B |
Dividend Yield | 3.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
